The Effects of Curcumin on Diabetes Mellitus: A Systematic Review.
Ledyane Taynara Marton,Laís Maria Pescinini-e-Salzedas,Maria Eduarda Côrtes Camargo,Sandra Maria Barbalho,Jesselina Francisco dos Santos Haber,Renata Vargas Sinatora,Cláudia Rucco Penteado Detregiachi,Raul José Silva Girio,Daniela Vieira Buchaim,Patrícia Cincotto dos Santos Bueno +9 more
Reads0
Chats0
TLDR
In this article, the effects of Curcuma longa or curcumin on patients with Type II diabetes mellitus were systematically reviewed, and the final selection included sixteen studies that fulfilled the inclusion criteria.Abstract:
Diabetes mellitus (DM) is an ensemble of metabolic conditions that have reached pandemic proportions worldwide. Pathology's multifactorial nature makes patient management, including lifelong drug therapy and lifestyle modification, extremely challenging. Currently, there is growing evidence about the effectiveness of using herbal supplements in preventing and controlling DM. Curcumin is a bioactive component found Curcuma longa, which exhibits several physiological and pharmacological properties such as antioxidant, anti-inflammatory, anticancer, neuroprotective, and anti-diabetic activities. For these reasons, our objective is to systematically review the effects of Curcuma longa or curcumin on DM. Databases such as PUBMED and EMBASE were searched, and the final selection included sixteen studies that fulfilled the inclusion criteria. The results showed that curcumin's anti-diabetic activity might be due to its capacity to suppress oxidative stress and inflammatory process. Also, it significantly reduces fasting blood glucose, glycated hemoglobin, and body mass index. Nanocurcumin is also associated with a significant reduction in triglycerides, VLDL-c, total cholesterol, LDL-c, HDL-c, serum C reactive protein, and plasma malonaldehyde. Therefore, it can be considered in the therapeutic approach of patients with DM.read more
Citations
More filters
Journal ArticleDOI
Role of Oxidative Stress in Diabetic Cardiomyopathy
Bart De Geest,Mudit Mishra +1 more
TL;DR: Investigations in animal models of diabetic cardiomyopathy have consistently demonstrated that increased expression of the primary antioxidant enzymes attenuates myocardial pathology and improves cardiac function.
Journal ArticleDOI
Chronic Inflammation in Non-Healing Skin Wounds and Promising Natural Bioactive Compounds Treatment
TL;DR: The role of the immune system, the involvement of inflammatory mediators and reactive oxygen species, the complication of bacterial infections in chronic wound healing, and the still-underexplored potential of natural bioactive compounds in wound treatment are discussed.
Journal ArticleDOI
Pharmacologically Active Phytomolecules Isolated from Traditional Antidiabetic Plants and Their Therapeutic Role for the Management of Diabetes Mellitus
Prawej Ansari,SM Quamrul Akther,J.M.A. Hannan,Veronique Seidel,Nusrat Jahan Nujat,Yasser Abdel-Wahab +5 more
TL;DR: This review article has focused on pharmacologically active phytomolecules isolated from medicinal plants presenting antidiabetic activity and the role they play in the treatment and management of diabetes.
Journal ArticleDOI
Efficacy and Safety of Curcumin Supplement on Improvement of Insulin Resistance in People with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
TL;DR: In this article, the effects of curcumin versus placebo or western medicine in patients with Type 2 diabetes mellitus (T2DM) were evaluated in four randomized controlled trials.
Journal ArticleDOI
Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells.
Vivek Kumar Soni,Arundhati Mehta,Yashwant Kumar Ratre,Vikas Chandra,Dhananjay Shukla,Ajay Kumar,Naveen Kumar Vishvakarma +6 more
TL;DR: In this paper, the ability of curcumin against high glucose-induced chemoresistance was investigated using hepatic carcinoma HepG2 cells, and it was shown that high glucose induces chemorexorubicin and drug-induced chromatin compactness along with declined expression of drug efflux pump MDR-1.
References
More filters
Journal ArticleDOI
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +10 more
TL;DR: An Explanation and Elaboration of the PRISMA Statement is presented and updated guidelines for the reporting of systematic reviews and meta-analyses are presented.
Journal ArticleDOI
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +9 more
TL;DR: The meaning and rationale for each checklist item is explained, and an example of good reporting is included and, where possible, references to relevant empirical studies and methodological literature are included.
Journal ArticleDOI
Oxidative stress and diabetic complications
TL;DR: Athrosclerosis and cardiomyopathy in type 2 diabetes are caused in part by pathway-selective insulin resistance, which increases mitochondrial ROS production from free fatty acids and by inactivation of antiatherosclerosis enzymes by ROS.
Journal ArticleDOI
Curcumin: From ancient medicine to current clinical trials
TL;DR: Curcumin exhibits great promise as a therapeutic agent, and is currently in human clinical trials for a variety of conditions, including multiple myeloma, pancreatic cancer, myelodysplastic syndromes, colon cancer, psoriasis and Alzheimer’s disease.
Journal ArticleDOI
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
TL;DR: Some diabetes clinical practice guidelines now recommend that SGLT2 inhibitors with proven cardiovascular benefit be prioritized in patients with type 2 diabetes mellitus who have not achieved glycemic targets and who have prevalent atherosclerotic cardiovascular disease.